The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC).
Johanna C. Bendell
Disclosure not yet available
Christophe Tournigand
Disclosure not yet available
Mariusz Bednarczyk
Disclosure not yet available
Anna Swieboda-Sadlej
Disclosure not yet available
Ik-Joo Chung
Disclosure not yet available
Carlo Barone
Disclosure not yet available
Jamal Christo Tarazi
Disclosure not yet available
Brad Rosbrook
Disclosure not yet available
Alejandro Daniel Ricart
Disclosure not yet available
Alberto F. Sobrero
Disclosure not yet available